Clobetasol propionate
- Generic Name
- Clobetasol propionate
- Brand Names
- Clobex, Clodan, Dermovate, Impeklo, Impoyz, Olux, Temovate, Tovet
- Drug Type
- Small Molecule
- Chemical Formula
- C25H32ClFO5
- CAS Number
- 25122-46-7
- Unique Ingredient Identifier
- 779619577M
- Background
Clobetasol propionate is a prednisolone derivative with higher specificity for glucocorticoid receptors than mineralocorticoid receptors. It has demonstrated superior activity compared to fluocinonide and was first described in the literature in 1974.
Clobetasol Propionate was granted FDA approval on 27 December 1985.
- Indication
Clobetasol propionate is indicated to treat moderate to severe plaque psoriasis as well as inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
- Associated Conditions
- Alopecia, Severe Plaque psoriasis, Corticosteroid responsive, Inflammatory Dermatosis, Corticosteroid responsive, pruritic Dermatosis, Moderate Plaque psoriasis, Moderate Scalp Psoriasis, Severe Scalp Psoriasis
Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 305
- Registration Number
- NCT00658788
- Locations
- 🇺🇸
J&J Studies, Inc, College Station, Texas, United States
🇺🇸Mount Sinai Department of Dermatology, New York, New York, United States
🇺🇸Virginia Clinical Research, Inc, Norfolk, Virginia, United States
Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis
- First Posted Date
- 2007-05-07
- Last Posted Date
- 2016-10-05
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 9
- Registration Number
- NCT00470392
- Locations
- 🇺🇸
VA Medical Center, Cleveland, Cleveland, Ohio, United States
🇺🇸University Hospital Case Medical Center, Cleveland, Ohio, United States
A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 78
- Registration Number
- NCT00436540
- Locations
- 🇺🇸
Central Dermatology, PC, Saint Louis, Missouri, United States
🇺🇸Solano Clinical Research, Vallejo, California, United States
Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 2488
- Registration Number
- NCT00437216
- Locations
- 🇺🇸
DHC Dimensional HealthCare, Inc. (Clinical Research Organization), Cedar Knolls, New Jersey, United States
Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 122
- Registration Number
- NCT00437255
- Locations
- 🇺🇸
Minnesota Clinical Study Center, Fridley, Minnesota, United States
🇺🇸J & S Studies, Inc., Bryan, Texas, United States
🇺🇸Baylor Research Institute, Dallas, Texas, United States
Maintenance Effect of Clobex Shampoo on Participants With Moderate to Severe Scalp Psoriasis
- Conditions
- Scalp Psoriasis
- Interventions
- First Posted Date
- 2006-11-17
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 288
- Registration Number
- NCT00400725
- Locations
- 🇨🇦
centre de Recherche Dermatologique du Québec, Quebec, Canada
Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus
- Conditions
- Lichen Sclerosus
- Interventions
- First Posted Date
- 2006-10-27
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- Center for Vulvovaginal Disorders
- Target Recruit Count
- 38
- Registration Number
- NCT00393263
- Locations
- 🇺🇸
Center for VulvoVaginal Disorders, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.